Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03148990
Other study ID # ASCLIN 002/2017
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date November 20, 2018
Est. completion date August 12, 2020

Study information

Verified date May 2019
Source The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Measles and rubella are highly contagious acute viral diseases. As per WHO, several evidences demonstrate the benefit for providing the universal access to vaccines containing measles and rubella antigens, mainly due to, respectively, mortality in children and malformations in fetuses. This is a Phase I-III, Controlled, randomized and double blind for the evaluation double viral vaccine anti-measles and rubella (MR), which is developed and produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings. 432 eligible volunteers (11-month-old infants), will be vaccinated and monitored for local and systemic adverse events and titration of antibodies. The study will last 11 months in total.


Description:

This is a Phase II-III, controlled, randomized and double blind for the evaluation of a double viral vaccine anti measles and rubella (MR), which is under the development at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings. 432 eligible volunteers (11-month-old infants), will be vaccinated and monitored for local and systemic adverse events and immunogenicity. The study will last 11 months in total.


Recruitment information / eligibility

Status Completed
Enrollment 432
Est. completion date August 12, 2020
Est. primary completion date August 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Months to 11 Months
Eligibility Inclusion Criteria:

- Both sex;

- Good health (no significant medical history);

- 11 months of age on the first dose of vaccine;

- To be up-to-date with the national vaccination calendar;

- Availability for follow-up throughout the study period;

- Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);

- Willing to strictly follow the study protocol;

- At least one legal guardian of the research participants must be able to understand and sign the informed consent form;

- Legal guardians by the research participants who can understand the child's inability to participate in another clinical trial during the time they are participating in the study;

- Legal guardian with intellectual capacity to fill out the signs of signs and symptoms at home.

Exclusion Criteria:

- Previous vaccination against measles and rubella;

- Personal history of measles or rubella;

- Personal history of anaphylactic shock, asthma, urticaria or other hypersensitivity reaction to previous vaccinations, or who are allergic or hypersensitive to vaccine components of the study;

- Use of antiallergic injections with antigens within 14 days or less prior to vaccination;

- Use of immunoglobulin in the last 12 months prior to vaccination;

- Use of blood products in the last 12 months prior to vaccination;

- Use of any type of vaccine less than 30 days prior to study vaccination;

- Use of injectable vaccines less than 42 days after study vaccination;

- Chronic use of any medications (except homeopathic medicines and trivial medication such as saline and vitamins);

- Previous use of immunosuppressive or cytotoxic medication;

- Use of systemic therapy with high doses of steroids;

- Use of any type of medication in a clinical trial within 12 months prior to vaccination;

- Personal history of clinically significant neurological, cardiovascular, respiratory, hepatic, renal, haematological, rheumatologic or autoimmune diseases;

- Personal history of coagulopathies diagnosed by a physician or report of capillary fragility;

- Personal history of seizures;

- Personal history of an active (eg any cancer) or treated malignant disease that may recur during the study;

- Personal history of sickle cell anemia;

- Asplenia (absence of spleen or removal of the spleen);

- HIV positive or history of any immunosuppressive disease;

- Presence of any disorder which, in the opinion of the principal investigator, may interfere with the evaluation of the study objectives;

- Legal guardian with limited capacity for adherence to the study, according to the researcher's evaluation;

- Impossibility of blood collection for pre-vaccine evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Measles and Rubella vaccine
Administration of the experimental vaccine (MR).
Measles, Mumps and Rubella vaccine
Administration of the comparator vaccine (MMR).

Locations

Country Name City State
Brazil Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda (CPCLIN) Natal Rio Grande Do Norte
Brazil Secretaria Municipal de Saúde do Estado do Rio de Janeiro Rio de Janeiro

Sponsors (2)

Lead Sponsor Collaborator
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) Oswaldo Cruz Institute

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity analysis of the study vaccine To evaluate imune response between post and pre-vaccination antibodies. 42 days after the 1st dose of MR or MMR
Secondary Reatogenicity analysis of the study vaccine To assess the occurrence of serious adverse events among individuals who received MR and MMR vaccines. 30 days after the 1st dose of MR or MMR
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4